Symposium @ Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting
Friday, November 6, 2026 12:30pm - 1:30pm
Lunch Included
SYNC-T® Therapy SV-102: A Combination Drug/Device Immunotherapy Approach for Metastatic Prostate Cancer: Updated Long-Term Overall Survival
Join us to learn more about the updated SYNC-T Therapy SV-102 long-term overall survival data presented at ESMO 2026
West Building - 300 Level - 224B
Lunch included, seating is limited
Symposium Overview
Description of program and speakers
Title: SYNC-T® Therapy SV-102: A Combination Drug/Device Immunotherapy Approach for Metastatic Prostate Cancer: Updated Long-Term Overall Survival
Speakers: Gerald Andriole, M.D. (Chief Medical Officer, Urology, Syncromune), Yousef Zakharia, M.D. (Chair, Genitourinary Malignancy Disease Group, Mayo Clinic Arizona), and Akash Patnaik, M.D., Ph.D., MMSc (Associate Professor of Medicine, University of Chicago)
Description:Â Leading investigators and clinical innovators will provide in-depth insights into SYNC-T SV-102, a novel combination intratumoral/locoregional immunotherapy designed to elicit a systemic antitumor response in patients with metastatic castration-resistant prostate cancer (mCRPC).
This session will showcase Phase 1 clinical results demonstrating safety, immune activation, and early signs of efficacy, and highlighting new long-term overall survival data recently presented at ESMO 2026.
The symposium will also spotlight the LEGION-100 Phase 2 clinical trial, now actively enrolling patients and recruiting clinical trial sites across the U.S. Investigators will share insights into the trial’s design, scientific rationale, and the opportunity for institutions to partner in evaluating this cutting-edge immunotherapy.
Key Topics
Immunotherapy in mCRPC
Trials and data to date.
Novel in situ SYNC-T Therapy
Combination intratumoral / locoregional
Phase 1 Long-Term OS Data
Phase 1 data in mCRPC
LEGION-100 Phase 2 Trial for mCRPC
Trial design, rationale, participation.
Speakers
The symposium will feature three speakers who have broad expertise on the SYNC-T Therapy
Gerald Andriole, M.D.
Chief Medical Officer, Urology, Syncromune, Inc.
Yousef Zakharia, M.D.
Chair, Genitourinary Malignancy Disease Group, Mayo Clinic Arizona
Akash Patnaik, M.D., Ph.D., MMSc
Associate Professor of Medicine, University of Chicago
Program Details
12:30pm – 1:30pm
12:30pm - 12:45pm
Gerald Andriole, M.D.
12:45pm - 1:05pm
Yousef Zakharia, M.D.
1:05pm - 1:20pm
Akash Patnaik, MD, PhD, MMSc
1:20pm - 1:30pm
Conference Directions
West Building, 300 Level – 224B
Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting
Phoenix Convention Center
100 N. 3rd St.
Phoenix, AZ 85004
602-262-6225
West Building – 300 Level – 224B
About Syncromune
Pioneers in Combination Multi-Target Intratumoral Immunotherapy
- Developing SYNC-T, a potentially first-in-class platform combination immunotherapy designed to address major unmet needs and treatment challenges of incurable metastatic solid tumors
- SYNC-T is an investigational in situ personalized cancer therapy engineered to synchronize the location of patient-specific tumor antigens, our multi-target immunomodulatory biologic, and immune cells in the tumor-draining lymph nodes to potentially create conditions for T cell activation to elicit a potential systemic anti-tumor response
- Our lead candidate, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer (mCRPC), is being evaluated in the LEGION-100 U.S., multicenter, Phase 2 trial. For more information, please visit www.legion100trial.com